EUVIMEDEUVIMED entdecken
Open Access

Timing of chronic subdural hematoma treatment affects middle meningeal artery embolization outcome

Naoya Imai, Takayuki Kato, Yohei Ito, Ryo Morishima, Tatsuki Aki, Shin-Ichi Shirakami

Surgical Neurology International · 21.06.2024 · 15 · 214

DOI: 10.25259/sni_293_2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgical Neurology International, online erschienen am 21.06.2024. Verfasst von Naoya Imai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Minokamo, Japan. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic subdural hematoma (CSDH) is a condition that tends to recur frequently. Although middle meningeal artery embolization (MMAE) is an effective CSDH treatment, there is currently no consensus regarding the optimal timing for embolization.

Methods

In this single-center and retrospective study, we reviewed 72 cases with 1 st -time recurrent CSDH from January 2018 to July 2023 and identified those treated with MMAE to examine its effect and the impact of differences in the timing of treatment.

Results

Of the 72 cases with CSDH recurrence for the 1 st time (mean age: 80.4 ± 9.7 years; men: 62 [86.1%]; mean first recurrence interval: 33 ± 24 days), 27 (37.5%) experienced a second recurrence. The mean first recurrence interval was shorter in cases with a second recurrence compared to cured cases: 24.3 ± 18.6 versus 38.3 ± 25.6 days, respectively ( P = 0.005). MMAE was performed in 17 (23.6%) cases (mean age: 82 ± 6.2 years; men: 14 [82.4%]). The mean time from initial surgical treatment to embolization was 52.4 ± 35.4 days, and the mean recurrence interval before MMAE was 24.9 ± 19.6 days. Six cases (35.3%) experienced post-embolization recurrence and required surgical treatment. The mean recurrence interval before MMAE was shorter in cases with recurrence after MMAE (15 ± 6.4 vs. 30 ± 22.1 days, P = 0.023). The time from initial surgical treatment to embolization was significantly shorter: 31.3 ± 12.8 versus 63.9 ± 38.9 days ( P = 0.039).

Conclusion

Cases with a short first recurrence interval were more likely to experience a second recurrence. Repeated recurrences within a short time increased the likelihood of post-embolization recurrence. MMAE performed early following the initial surgical treatment increased the recurrence risk.

Schlagwörter

Stichwörter der Autor:innen

Chronic subdural hematomaEmbolizationEndovascular therapyRecurrence

Autor:innen und Institutionen

  • Department of Neurosurgery, Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Minokamo, Japan.
  • Department of Neurosurgery, Daiyukai General Hospital, Ichinomiya, Japan.
  • Department of Neurosurgery, National Hospital Organization Toyohashi Medical Center, Toyohashi, Japan.

Zitieren

APA

Imai, N., Kato, T., Ito, Y., Morishima, R., Aki, T., & Shirakami, S. I. (2024). Timing of chronic subdural hematoma treatment affects middle meningeal artery embolization outcome. Surgical Neurology International, 15, 214. https://doi.org/10.25259/sni_293_2024

Vancouver

Imai N, Kato T, Ito Y, Morishima R, Aki T, Shirakami SI. Timing of chronic subdural hematoma treatment affects middle meningeal artery embolization outcome. Surgical Neurology International. 2024;15:214. doi:10.25259/sni_293_2024

BibTeX
@article{Imai2024,
  author = {Imai, Naoya and Kato, Takayuki and Ito, Yohei and Morishima, Ryo and Aki, Tatsuki and Shirakami, Shin-Ichi},
  title = {Timing of chronic subdural hematoma treatment affects middle meningeal artery embolization outcome},
  journal = {Surgical Neurology International},
  year = {2024},
  volume = {15},
  pages = {214},
  doi = {10.25259/sni_293_2024}
}
Kostenlos starten →